solid end year set top-line
pipelin
back track guid in-lin lt algorithm
miss mark close year solid note organ sale
growth y/i vs ep fy outlook in-lin long-
term target rang reiter expect recent deal waterpik
flawless area debat given rocki result post-deal close follow
gross margin beat heavi market sale
setup
call organ sale growth consum domest
specialti get total compani inclus
exit achiev target view support number new
product includ arm hammer clean simpl oxiclean laundri deterg
well innov across oxiclean batist waterpik flawless arm hammer
toothpast trojan vitafus brand number put take
digest year includ wind-down oxiclean laundri exit privat label
vitamin lap acquisit account flawless categori posit
look solid competit threat manag ep expect
rang y/i underli growth benefit
addit flawless hit tariff market new launch
maintain forecast organ sale growth ep
slightli high-end chd outlook rang rais price object
base target price-to-earnings ep estim turn
turn premium target peer group averag compar level past
believ adequ reflect expect return histor abil
deliv consist strong result albeit less gap perform rel
group averag peer also improv reiter buy
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
church dwight manufactur household
person care specialti product
brand arm hammer oxiclean trojan
spinbrush oper three segment
consum domest consum intern
account sale profit
geograph us account sale
result one
consist stapl group help value-
product solid manag cost disciplin
promot activ abat largest
categori valuat come high
weve seen broadli quarter among hpc peer beat sale gross
margin funnel spend back busi result ep in-lin
expect organ sale beat estim ep
in-lin consensu confirm return algorithm outlook
organ sale growth high singl digit ep growth back
half mute market expect setup
better increment flawless distribut hit shelv acquisit account
normal innov begin roll spend bear fruit
equiti earn affili
tabl margin segment perform
revenu segment
tabl organ growth breakdown segment
proport sale
cog ex-charg gain
sale
sale
depreci amort
equiti earn affili
ep continu oper
cog ex-charg gain
gross profit ex-charg gain
sale
sale
sale
equiti earn affili
after-tax interest cost convert debt
ep continu oper
price object deriv use target price-to-earnings ep estim
premium target peer group averag abil
continu deliv consist best class result albeit less gap
perform peer also improv
downsid risk greater-than-expect competit key categori meaning
deceler sale earn growth faster-than-expect rotat
compani greater intern exposur acquisit view
olivia tong cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
helen troy
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
